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Introduction
This issue’s review contains, like always, a nice series of new
data that hopefully satisfies the interest of the reader. No real
theme, but a host of different developments.
Biology of lymphoma
As is well known, the process of antigen receptor rearrange-
ments can lead to mistakes resulting in oncogenic chromo-
somal translocations. The enzyme activation-induced cytidine
deaminase (AID) plays a role in the initiation of class
switching in B-lymphocytes, and therefore, its expression is
tightly controlled by the phosphatidylinositol 3-kinase δ
(PI3Kδ) pathway. Compagno et al. [1] show that treatment
of primary mouse B cells with idelalisib or duvelisib, and to
a lesser extent ibrutinib, enhances the expression of AID
resulting in increased frequency of somatic hypermutation
and chromosomal translocation, not only of the IgH locus
but also to several other sites in the genome. Furthermore, in
mice, PI3Kδ inhibitors or ibrutinib increases the formation of
AID-dependent tumors. Consistently, PI3Kδ inhibitors en-
hanced AID expression and translocation frequency to IGH
and other sites in human chronic lymphocytic leukemia (CLL)
and mantle cell lymphoma (MCL) cell lines, and, finally, in
patients treated with idelalisib, but not ibrutinib, there is in-
creased somatic hypermutation in the genome. This
worrisome effect should be carefully monitored in patients
treated with these agents, especially since patients are often
treated for a long time and the effects maybe be seen only after
quite some time.
Classification (and understanding!) of tumors is based on the
cell of origin concept. Very distinct malignancies like classical
Hodgkin lymphoma (cHL), CLL, andmultiple myeloma (MM)
arise from B lymphocytes, but have various stages of differen-
tiation. Law et al. [2] performed a large-scale genome-wide
association study in many patients (CLL: n = 1842; HL:
n = 1465; MM: n = 3790) to see whether there might be a
common predisposition for B cell lineage-derived neoplasia.
They identified a risk locus at 3q22.2 with opposing effects
between CLL and cHL. Eight established non-HLA risk loci
showed also pleiotropic associations. Within the HLA region,
Ser37 + Phe37 in HLA-DRB1 was associated with increased
CLL and cHL risk and reduced MM risk, and Gly70 in HLA-
DQB1 showed opposing effects between CLL and cHL. These
data identify shared biological pathways influencing the devel-
opment of CLL, HL, andMM but with opposing risks and thus
maybe are active at various stages of B cell development.
Hodgkin lymphoma
HL remains an enigmatic disease with so many different ab-
errant processes involved. Zahn et al. [3] add a new mecha-
nism, namely the presence of a truncated form of PTPN1 in
cHL cells (both in cell lines and in tissues), which upregulates
Janus kinase/signal transducer and activator of transcription
(JAK/STAT) activity, a common feature of B cell lymphomas.
Functional characterization of this variant further indicated
that it leads to proliferation and reduced sensitivity to chemo-
therapy. This latter finding is a bit surprising, cHL being one
of the earliest and well-known diseases curable by chemother-
apy. Another new mechanism in HL is described by
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Agostinelli et al. [4]. They analyzed the functional status of
glycogen synthase kinase-3 beta (GSK-3β) in cHL using an-
tibodies raised against fixation-resistant epitopes of phospho
Y216 GSK-3β (active form), phospho S9 GSK-3β (inactive
form), and β-catenin protein. GSK-3β is a serine/threonine
kinase involved in glycogen metabolism, cell cycle progres-
sion, differentiation, embryogenesis, migration, metabolism,
survival, and cellular senescence. Its main biological function
is to inhibit β-catenin by sequestration, and promotion of its
proteasomal degradation in the Wnt canonical pathway. The
active form of the enzyme was detected in 100 of 100 (100%)
of the cases, and in line with that, the β-catenin protein was
expressed in only 12 of 100 (12%) of the samples. These
findings imply that activation of GSK-3β in cHL results in
inhibition of the Wnt/β-catenin signal cascade and the aber-
rant accumulation of its activated form in nuclei of Reed-
Sternberg and Hodgkin cells. A third new mechanism is de-
scribed by Etzel et al. [5]. Because it is known that survival
and proliferation of Hodgkin and Reed-Sternberg (HRS) cells
are dependent on constitutive activation of nuclear factor κB
(NF-κB) they looked for mutations in TNF alpha-induced
protein 3 (TNFAIP3), one of the inhibitors of NF-κB. In addi-
tion, they evaluated protein expression by immunohistochem-
istry. Of the 37 investigated cHL cases, 8 (22%) had a muta-
tion and these tended to be negative by immunohistochemis-
try. All these cases were negative for EBV which suggests
complementing functions of TNFAIP3 inactivation and EBV
infection in cHL pathogenesis.
The same gene was studied by Jung et al. [6] in ocular
marginal zone lymphoma (oMZL). They analyzed 10 cases
using whole-genome and RNA sequencing and an additional
38 cases with targeted sequencing. Major genetic alterations
affecting genes involved in NF-κB pathway activation (60%),
chromatin modification and transcriptional regulation (44%),
and B cell differentiation (23%) were identified. In whole-
genome sequencing, the 6q23.3 region containing TNFAIP3
was deleted in five samples (50%). In addition, five structural
variation breakpoints in the first intron of IL20RA located in
the 6q23.3 region were found in three samples (30%). In
targeted sequencing, a disruptive mutation of TNFAIP3 was
the most common alteration (54%), followed by mutations of
TBL1XR1 (18%), CREBBP (17%), and KMT2D (6%). All
TBL1XR1 mutations were located within the WD40 domain,
and TBL1XR1 mutants transfected into 293 T cells increased
TBL1XR1 binding with nuclear receptor corepressor
(NCoR), leading to increased degradation of NCoR and
the activation of NF-κB and JUN target genes. This study
confirms that genes involved in the activation of the
NF-κB signaling pathway are the major driver in the on-
cogenesis of ocular MZL, which is inline findings in MZL
at other sites, especially nodal based ones [7], which are, as
earlier described in this Journal, difficult to separate from
follicular lymphoma (FL) [8].
B cell lymphomas
Although the primary genetic alteration in FL, the t(14;18), is
among the earliest detected tumor-associated translocations,
the full pathogenesis is not clear. Especially, the importance
of the tumor stroma is recognized but not understood. Pandey
et al. [9] demonstrate that FL stromal cells overexpress
CXCL12. Interleukin-4 (IL-4) high FL-TFH cells, unlike FL
B cells themselves, trigger CXCL12 upregulation in human
stromal cell precursors. In agreement, they found that expres-
sion of CXCL12 is associated with IL-4 expression and sig-
naling within the FL stroma. In an in vitro model, they con-
firmed that the IL-4/CXCL12 axis was amplified in activated
lymphoid stromal cells. Finally, CXCL12 triggers primary FL
B cell activation, migration, and adhesion, a process antago-
nized by BTK and PI3K inhibitors. These data identify the IL-
4/CXCL12 loop as a previously unrecognized pathway in-
volved in FL stroma and as a potential therapeutic target in
FL patients.
It is well known that activated B cell-like (ABC) and ger-
minal center B cell-like (GCB) diffuse large B cell lymphoma
(DLBCL) represent the two major molecular DLBCL sub-
types. They are characterized by differences in clinical course
and by divergent addiction to oncogenic pathways. Erdmann
et al. [10] determined activity of novel compounds in these
two subtypes by conducting an unbiased pharmacologic
in vitro screen. The PI3K alpha/delta (PI3Kα/δ) inhibitor
AZD8835 showed marked potency in ABC DLBCL cells,
whereas the protein kinase B (AKT) inhibitor AZD5363 in-
duced apoptosis in PTEN-deficient DLBCLs irrespective of
the molecular subtype. These in vitro results were confirmed
in various cell line xenograft and patient-derived xenograft
mouse models in vivo. Treatment with AZD8835 induced
inhibition of NF-κB signaling, prompting us to combine
AZD8835 with the Bruton’s tyrosine kinase inhibitor
ibrutinib. This combination was synergistic and effective both
in vitro and in vivo. In contrast, the AKT inhibitor AZD5363
was effective in PTEN-deficient DLBCLs through downreg-
ulation of the oncogenic transcription factor MYC. These data
suggest that patients should be stratified according to their
oncogenic dependencies when treated with PI3K and AKT
inhibitors. Of course, this needs conformation in the clinical
setting.
Components of the B cell receptor (BCR) signaling path-
way represent promising therapeutic targets in DLBCL and
other B cell malignancies. MYC, a transcriptional factor and
oncoprotein, is overexpressed in a proportion of DLBCL and
indicates poor prognosis and aggressive clinical course. Wang
et al. [11] tried to elucidate the BCR signaling pathway in
MYC-positive DLBCL by analyzing the levels of BCR-
associated genes according to MYC gene status and outcome.
They found that CD19, SYK, and BLKwere highly expressed
in DLBCL with MYC gene overexpression. MYC-positive
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DLBCL had higher levels of pSYK and pBLK, but only
pSYK level correlated with patient survival. In vitro studies
demonstrated that overexpression of the MYC gene augment-
ed BCR signaling, whereas MYC gene knockdown attenuated
BCR signaling. Thus, MYC protein-positive DLBCL features
highly activated BCR signaling and may represent a potential
candidate for BCR inhibitor therapy.
T cell lymphoma
Refractory coeliac disease (rCD) is a problematic condition in
which about 50% of cases develop into an aggressive incur-
able T cell lymphoma, enteropathy-associated T cell lympho-
ma (EATL). Although rCD was recently redefined according
to the WHO classification, the present literature still uses the
distinction into two types, rCD I and rCDII. Ritter et al. [12]
performed high-throughput sequencing of the TCRβ rear-
rangements and compared the results from duodenal mucosa
specimens of controls (n = 9), patients with active CD
(n = 10), CD patients on a gluten-free diet (n = 9), rCD type
I (n = 8), rCD type II (n = 8), and unclassified Marsh I cases
(n = 3) collected from 2002 to 2013. On average, 106 sequence
reads per sample were generated consisting of up to 900 indi-
vidual TCRβ rearrangements. In rCD type II, the most fre-
quent clonotypes (i.e., sequence reads with identical CDR3)
represent in average 43% of all, which was significantly
higher than that in controls (6.8%) or rCD type I (6.7%).
Repeat endoscopies in individual patients revealed stability
of clonotypes for up to several years without clinical symp-
toms of EATL. Dominant clonotypes identified in individual
patients with rCD type II were unique and not related between
patients. CD-associated, gliadin-dependent CDR3 motifs
were only detectable at low frequencies. These results support
the assumption that the clonal T cells expand independent of
gluten stimulation. This work adds significantly to the knowl-
edge on this disease, which had been widely investigated.
Nevertheless, it is a very rare condition according to van
Wanrooij et al. [13]. They evaluated the 106 CD patients
who were referred to their tertiary referral center between
January 2006 and December 2011 for evaluation of non-
responsive CD. In addition, a questionnaire was sent to all
82 gastroenterology departments in the Netherlands to reveal
whether a patient with rCD was currently being evaluated or
had been treated between 2006 and 2012. During this 6-year
period, a total of 31 patients were diagnosed with rCD (19
rCD I and 12 rCD II). The nationwide survey revealed five
additional patients with rCD I and one patient with rCD II.
This leads to an annual incidence of rCD of 0.83/10.000 CD
patients. The remaining patients with non-responsive CD
were diagnosed with involuntary gluten ingestion (21.7%),
delayed mucosal recovery (11.3%), enteropathy-associated T
cell lymphoma (7.5%), and autoimmune enteropathy (1.8%).
This well-conducted nationwide study reveals a very low
incidence of rCD in the Netherlands. Nevertheless, rCD is a
clinically relevant disease entity in CD patients non-
responsive to the gluten-free diet.
Angioimmunoblastic T cell lymphoma (AITL) originates
from follicular helper T cells and is characterized by a poly-
morphic infiltrate with the neoplastic T cells forming small
clusters around the follicle and high endothelial venules.
Wang et al. [14] performed whole-exome sequencing in nine
cases of AITL from Taiwan (n = 6) and U.K. (n = 3). They
confirmed frequent mutations in TET2 (9/9), DNMT3A (3/9),
IDH2 (3/9), RHOA (3/9), and PLCG1 (2/9). Furthermore,
they identified mutations in TNFRSF21 (1/9), CCND3 (1/9),
and SAMSN1 (1/9), which had not yet been implicated in the
pathogenesis of AITL. McKinney et al. [15] performed a sim-
ilar analysis in 68 cases of hepatosplenic T cell lymphoma
(HSTL), a rare and lethal lymphoma. Chromatin-modifying
genes, including SETD2, INO80, and ARID1B, were mutated
in 62%; there were frequent mutations in STAT5B (31%),
STAT3 (9%), and PIK3CD (9%). In addition, they noted less
frequent events in EZH2, KRAS, and TP53. SETD2 was the
most frequently silenced gene in HSTL. For some of these
genetic events, targeted treatments have been described in
other tumors and thus, these might be also effective in AITL.
Epidemiology of lymphoma
Prevention of cancer is potentially a very important tool in
decreasing its toll. The incidence of several forms of cancer
is influenced by life style factors including smoking and diet.
Han et al. [16] reviewed 221 published cohort and case-
control studies that reported relative risk (RR) of non-
Hodgkin lymphoma (NHL) and fat intake using PubMed,
Cochrane, EMBASE, and Google Scholar databases. Only
10 of 221 studies (two cohort and eight case-control studies)
were relevant to this meta-analysis. There was a significant
association between total fat consumption and increased risk
of NHL (RR = 1.26); in addition, subgroup analysis showed a
significant correlation with DLBCL (RR = 1.41) but not with
FL (RR = 1.21), CLL (RR = 0.91), nor with T cell lymphoma
(RR = 1.12). These findings further indicate that different
lymphoma types are really different diseases. However, reduc-
ing fat intake has probably more effect on other diseases than
on the incidence of DLBCL. Kleinstern et al. [17] performed
an interesting study on lifestyle risk factors for B-NHL. In a
case-control study, they investigated self-reported medical and
lifestyle exposures, for overall B-NHL and subtypes among
Palestinian Arabs (PA) and Israeli Jews (IJ). They recruited
823 cases and 808 healthy controls. Among 307 PA/516 IJ, B-
NHL cases subtype distributions differed, with DLBCL being
prominent among PA (71%) compared to IJ (41%); FL was
observed in 14 versus 28%, and MZL, in 2 versus 14%, re-
spectively. Overall B-NHL in both populations was associated
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with recreational sun exposure (RR = 1.43), black hair-dye
use (RR = 1.70), hospitalization for infection (RR = 1.68),
and first-degree relative with hematopoietic cancer
(RR = 1.69). An inverse association was noted with alcohol
use (RR = 0.46). Subtype-specific exposures included
smoking (FL, RR = 1.46) and more of ten monthly indoor
pesticide use (DLBCL, RR = 2.01). Associations observed
for overall B-NHL in PA only, included gardening
(RR = 1.93) and history of herpes, mononucleosis, rubella,
and blood transfusion (RR > 2.5), while for IJ, risk factors
included growing fruits and vegetables (RR = 1.87) and self-
reported autoimmune diseases (RR = 1.99). It is quite inter-
esting that they found in two geographically proximate popu-
lations some unique risk factors for B-NHL. Heterogeneity in
the observed associations by ethnicity could reflect differ-
ences in lifestyle, medical systems, and reporting patterns,
while, like in the previous study, variations by histology infer
specific etiologic factors for lymphoma subtypes.
Dhakal et al. [18] evaluated the effect of radiotherapy (RX)
for ocular adnexal lymphoproliferative disorders (OALDs) in
112 patients, 71 MZL and 41 other types of lymphoma. Fifty-
six patients with MZL OALD and 26 patients with non-MZL
received RX only. Complete remission was achieved in 49
(87.5%) patients in the MZL cohort and 23 (88.4%) in the
non-MZL cohort. Local recurrence occurred in four (7.1%)
patients in the MZL cohort, compared with four (15.3%) pa-
tients in the non-MZL cohort. The 5-year and 10-year disease-
free survival was 95 and 83% for the oMZL and 67 and 56%
for the non-MZL. On multivariate analyses, age, non-MZL
histology, and radiation dose <30 Gray were associated with
worse survival. These results indicate a high cure rate with
local therapy only.
Svendsen et al. [19] provide a good overview of their
experience with the rare eyelid lymphoma, a nice example
of international collaboration. Data from 86 patients were
collected from 7 international eye cancer centers
from1980–2015, indicating on average only one patient in
3 years! The cases included primary and secondary lym-
phomas affecting the eyelid. Mean age was 63 years and
47 (55%) were male. B cell lymphomas constituted 83%
(n = 71) and T cell lymphomas constituted 17% (n = 15).
The most common subtypes were MZL (37% [n = 32]), FL
(23% [n = 20]), DLBCL (10% [n = 9]), MCL (8% [n = 7]),
and mycosis fungoides (MF) (9% [n = 8]). EMZL had a
female predilection (69% [22 of 32]), whereas MCL (71%
[5 of 7]) and MF (88% [7 of 8]) had a male predominance.
MCL (57% [4 of 7]), DLBCL (56% [5 of 9]), and MF (88%
[7 of 8]) were frequently secondary involvement. Localized
EMZL and FL were mostly treated with external beam ra-
diation therapy, whereas DLBCL, MCL, and high Ann
Arbor stage EMZL and FL were frequently treated with
chemotherapy. DLBCL and MCL had a poor prognosis,
whereas EMZL, FL, and MF had a good prognosis.
More common is primary central nervous system lym-
phomas (PCNSL), still a rare lymphoma, with a poor
prognosis. Recently, an increased incidence has been re-
ported. The present study is a population-based study of
all patients with PCNSL in the Uppsala/Örebro region of
middle Sweden on 96 patients (50 female) with a mean
age of 66 (range 17–95). Enblad et al. [20] confirmed a
statistically significant increase in age-standardized inci-
dence. No patient had an HIV infection. Two patients had
undergone kidney transplantation and were treated with
immunosuppressive drugs. A high proportion of the pa-
tients, 29%, had a history of an autoimmune or inflamma-
tory disease. The prognosis was poor with a median sur-
vival of only 4 months. In the 70 (73%) patients treated
with curative intention, the median survival was
12 months. Patients treated with high-dose methotrexate,
radiotherapy, and/or temozolomide appeared to have a
better survival. There was no improvement in survival
during the study period or after the introduction of ritux-
imab. There also was no difference in any of the analyzed
variables that could explain the increased incidence.
Defining entities
B cell lymphomas
De Souza et al. [21] found IgG4 expression in 4 out of 30
patients (13%) with primary cutaneous (PC) MZL. Patients
with IgG4-positive lymphomas were 57 to 77 years of age
(mean, 69) at biopsy. The lesions were solitary in two patients
and were most commonly located on the trunk. Patients with
IgG4-negative lymphomas experienced earlier disease onset
at an average age of 53 years. The majority of the IgG4-
negative cases presented with localized disease, on the trunk
and upper extremities. There was no significant difference in
the IgG4-positive versus IgG4-negative cases for the follow-
ing parameters: Ig κ or λ restriction, B cell or T cell predom-
inance, and site of the lesions. Detection of IgG4 expression is
therefore not of diagnostic or clinical relevance.
Cao et al. [22] investigatedMYD88 and CXCR4mutations
in various IgM macroglobulinemia-associated diseases, in-
cluding Waldenstrom macroglobulinemia (WM), various
types of B cell non-Hodgkin’s lymphoma (NHL), MM, pri-
mary amyloidosis (AL), and monoclonal gammopathy of un-
determined significance (MGUS): IgM monoclonal
gammopathy-related diseases (IgM-RD). Of their cohort of
112 patients, 64 (57%) carried the MYD88 L265P mutation
and 14 patients (13%) carried the CXCR4 WHIM-like muta-
tion; MYD88 L265P in cases with WM (39/42), MGUS
(8/18), NHL (14/41, including 4/13 DLBCL, 1/8 eMZL, 3/6
(sMZL), 1/4 chronic lymphocytic leukemia, 2/3 nodal
(n)MZL, 1/2 MCL, 1 BL, and 1 B cell NHL that could not
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be classified), primary AL (2/2), and IgM-PN (1/1). The mu-
tation was absent in five patients with cryoglobulinemia, two
with primary cold agglutinin disease and one with MM. The
CXCR4 WHIM-like mutation was present in 10/42 patients
with WM, 3/41 with NHL (1 DLBCL, 1 SMZL, and 1
NMZL), and 1/18 patients with IgM MGUS. Among the pa-
tients with NHL, those with the mutated MYD88 L265P ge-
notype were younger and had lower level of IgG and IgA than
the patients with the wild-type genotype. The authors suggest
that MYD88 mutation status might be used to differentiate
among diseases, but in fact, their data do not give much hope
for that.
Rohde et al. [23] found in pediatric BL a mutation frequen-
cy of 78% for ID3, 13% for TCF3, and 36% for CCND3. ID3
and CCND3 mutations were associated with more advanced
stages of the disease and thus may represent a highly relevant
second hit in pediatric BL pathogenesis (adult cases were not
investigated).
Colomo et al. [24] investigated BL as well, but also cases of
DLBCL with MYC and BCL2/6 translocations to see whether
they could prescreen cases with immunohistochemistry to
avoid mutation testing in many DLBCL cases without MYC
translocation. LMO2 is a germinal center marker expressed in
most lymphomas originated in these cells. Because in gene
expression profiling studies, LMO2 downregulation is ob-
served in BL and DLBCL with MYC translocations, they ana-
lyzed LMO2 protein expression in 46 BLs and 284 BLBCL.
All 46 BL lymphomas had a MYC rearrangement and LMO2
was expressed in 1 (2%). LMO2 was also positive in 146/268
(55%) DLBCL cases, but only in 6/42 (14%) DLBCL with
MYC translocation and in 2/16 (12.5%) double hit lymphomas.
The relationship between LMO2 negativity and MYC translo-
cation was further analyzed in different subsets of tumors ac-
cording to CD10 expression and cell of origin. Lack of LMO2
expression was associated with the detection of MYC translo-
cations with high sensitivity (87%), specificity (87%), positive
predictive value and negative predictive value (74 and 94%,
respectively), and accuracy (87%) in CD10 DLBCL. This in-
dicates that LMO2 surpassed MYC in CD10 DLBCL as pre-
dictor of MYC status. Although the authors conclude that their
findings suggest that LMO2 loss may be a good predictor for
the presence of MYC translocation in CD10 DLBCL, I believe
that still too many cases are missed whilst the benefit of
avoiding mutation testing is only limited.
Bogisz et al. [25] are also interested in DLBCL with MYC
and BCL2, but focus on protein expression and found that in
cases with high expression of both, there is also high BCR-
mediated signaling using their previously identified signature
of active BCR signaling on formalin-fixed paraffin-embedded
specimens. Their findings suggest that the BCR signaling
pathway may be more active in MYC/BCL2 double-
expressor DLBCL and thus may represent a rational therapeu-
tic target in this aggressive DLBCL subgroup.
T cell lymphomas
According to Wang et al. [26]. it is worthwhile to pre-
screen anaplastic large cell lymphomas (ALCLs) with
p63 immunohistochemistry to select for cases with chro-
mosomal rearrangements of the TP53 homolog TP63, an
indicator of aggressive clinical behavior. Of their 116
ALCLs, 35% were positive for p63 protein. Primary
cutaneous and anaplastic lymphoma kinase (ALK)-neg-
ative ALCLs were more frequently positive than ALK-
positive ALCLs. Cases with TP63 gene rearrangements
showed uniform p63 expression. In nonrearranged cases,
p63 expression was associated with extra copies of
TP63 on 3q28, which correlated with extra copies of
the DUSP22 locus on 6p25.3. Results of immunohisto-
chemistry, Western blotting, and RNA sequencing indi-
cated that p63 expression in nonrearranged cases was
entirely attributable to TAp63 isoforms. These findings
indicate that ALCLs without TP63 rearrangements may
express TAp63 isoforms of p63 and that this expression
is associated with extra copies of TP63, probably due to
widespread genomic copy number abnormalities rather
than focal gains. Immunohistochemistry for p63 in
ALCL is not specific for TP63 rearrangements but is
useful as a screening test to select cases for further
testing by fluorescence in situ hybridization (FISH).
Immunohistochemistry for ΔNp63 (p40) is not informa-
tive in the evaluation of ALCL.
Inhibition of the Janus kinase (JAK)-STAT pathway has
been implicated as a treatment option for extranodal natural
killer/T cell lymphoma, nasal type (NTCL) but a predictive
marker is not yet available. Sim et al. [27] found in 5 of 71
patients with NTCL (7%) JAK3 mutations in the
pseudokinase domain. Proliferation of Ba/F3 cells transduced
with these novel JAK3mutations was independent of IL-3 and
was inhibited by the JAK3 inhibitor tofacitinib. Although
phosphorylated STAT3was overexpressed in 35 of 68 patients
with NTCL (51%), a STAT3 mutation (p.Tyr640Phe;
STAT3Y640F) at the SRC homology 2 domain was detected
in only 1 of the 63 patients (<2%). A STAT3 inhibitor was
active against STAT3-mutant SNK-6 and YT cells. These re-
sults indicate that novel JAK3 mutations are oncogenic and
druggable in NTCL. The authors conclude that the JAK3 or
STAT3 signal was altered in NTCL, and pathway inhibition
might be a therapeutic option for patients with JAK3- or
STAT3-mutant NTCL.
New entities/subtypes
We are less than a year after the presentation of the updated,
but not new, WHO classification, but there is already quite
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some new data that show once again that a classification is
always work in progress.
It is well known that EBV can give rise to a large variation
of neoplasms, including a spectrum of lymphoproliferations in
various forms of immunodeficiency. Human herpesvirus 8
(HHV8)-associated lymphoid proliferations are way less com-
mon and poorly characterized disorders mainly affecting im-
munosuppressed patients, especially with HIV infection.
Now, based on 66 biopsies from 61 patients (47 HIV-positive),
Gonzalez-Farre et al. [28] describe the clinicopathological
spectrum of these lesions. The series consisted of 13 (20%)
cases of HHV8-related reactive lymphoid hyperplasia, 2 (3%)
HHV8 plasmablastic proliferations of the splenic red pulp, 28
(42%) multicentric Castleman disease, 6 (9%) germinotropic
lymphoproliferative disorders, and 17 (26%) HHV8-related
lymphomas. As expected, the pathologic diagnosis was pre-
dictive of overall survival. In addition to the classical presen-
tation of the different entities, they identified novel and over-
lapping features. Reactive HHV8 proliferations were fre-
quently associated with systemic symptoms but never
progressed to overt HHV8-positive lymphoma. Two cases
had a plasmablastic proliferation limited to spleen. Eight cases
of multicentric Castleman disease had a previously unrecog-
nized presentation shortly after the diagnosis of HIV infection,
six cases had cavity effusions, and three showed plasmablast-
enriched proliferations. One germinotropic lymphoprolifera-
tive disorder was EBV-negative and three occurred in HIV-
positive patients, who had distinctive clinical and morpholog-
ical features. Two of the HHV8-related lymphomas did not
fulfill the criteria for previously recognized entities. All these
findings expand the clinical and pathological spectrum of
HHV8-related lymphoid proliferations, which is broader than
currently recognized.
Boyer et al. [29] describe an interesting group of lesions,
based on their experience with 12 cases and review of the
literature. Previously, case reports presented localized fibrin-
associated Epstein-Barr virus (EBV)+ large B cell prolifera-
tions at unusual anatomic sites. These have been included in
the category of DLBCL associated with chronic inflammation
(DLBCL-CI) in the WHO classification. Median age was
55 years with a male:female ratio of 3. In their 12 cases, the
lymphoma was an incidental microscopic finding involving
atrial myxomas (n = 3), thrombi associated with endovascular
grafts (n = 3), chronic hematomas (n = 2), and pseudocysts
(n = 4). All cases tested were nongerminal center B cell origin,
type III EBV latency, and were negative for MYC rearrange-
ments and alternative lengthening of telomeres by FISH.Most
showed high CD30, Ki67, and PD-L1, and low to moderate
MYC and p53 expression. Among 11 patients with detailed
follow-up, 6 were treated surgically, 3 with cardiac or vascular
lesions had persistent/recurrent disease at intravascular sites,
and 4 died of causes not directly attributable to lymphoma.
Reports of previously published fibrin-associated cases
showed similar features, whereas traditional DLBCL-CI cases
with a mass lesion had significantly higher lymphoma-
associated mortality. Fibrin-associated EBV+ large B cell
lymphoma is clinicopathologically distinct from DLBCL-CI,
warranting separate classification. Most cases, particularly
those associated with pseudocysts, behave indolently with
the potential for cure by surgery alone and may represent a
form of EBV+ lymphoproliferative disease rather than lym-
phoma. However, primary cardiac or vascular disease may
have a higher risk of recurrence despite systemic chemother-
apy. These interesting lesions might have a relation with
EBV+ mucocutaneous ulcer.
Guitart et al. [30] provide further data from 34 patients with
primary cutaneous CD8-positive aggressive epidermotropic T
cell lymphoma, a rare and poorly characterized variant of cu-
taneous lymphoma, still considered a provisional entity in the
latest 2016 WHO classification update. The median age was
77 years (range 19–89 years) and presentation was primarily
with extensive annular necrotic plaques or tumor lesions with
frequent mucous membrane involvement. The 5-year survival
was 32% with a median survival of 12 months. A subset of 17
patients had a prodrome of chronic patches prior to the devel-
opment of aggressive ulcerative lesions. There were cases
with lack of CD8 or αβ T cell receptor expression yet with
similar clinical and pathological presentation. The authors rec-
ommend the term primary cutaneous aggressive
epidermotropic cytotoxic T cell lymphoma as this broader
designation better describes this clinical-pathologic presenta-
tion, which allows the inclusion of cases with CD8-negative
and/or αβ/γδ Tcell receptor chain double-positive or double-
negative expression.
Hu et al. [31] describe 12 patients with EBV-positive intes-
tinal T/natural killer (NK) cell lymphoma (ITNKL), an un-
common tumor with an extremely aggressive clinical behav-
ior. All patients had involvement of the small intestine with
concurrent lesions of the large intestine in two. Seven patients
(58%) had Lugano stages IIE/IV disease and eight (67%) were
categorized as high-intermediate/high-risk according to the
prognostic index for PTCL (PIT). Three patients (25%) with
an age of onset of less than 50 years had chronic active EBV
infection (CAEBV). Five CD56-positive patients (42%) had a
poorer prognosis than those without CD56 expression. NK
cell-type lymphoma defined by the absence of any TCR ex-
pression or clonal TCR-γ rearrangement was found in six
patients (50%). Interestingly, EBV positive intra-epithelial
lymphocytosis was observed in one case with a background
of CAEBV.
Pitfalls in lymphoma diagnosis
According to Tomasini et al. [32] chronic amastigote-negative
cutaneous leishmaniasis (CL) might be misdiagnosed as
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lymphoma. It is a diagnostic challenge, as the parasite load
may be low or absent in biopsy tissue sections. They analyzed
a series of consecutive biopsy specimens, taken from 130
patients with a diagnosis of granulomatous dermatitis of un-
known etiology. A total of 27 of 130 samples were positive for
Leishmania-specific DNA. In only three patients, a clinical
diagnosis CL was made. The lesions were single or multiple
nodules or plaques of many months of duration.
Histopathologically, a tuberculoid granulomatous dermatitis
was the least common denominator in every case, whilst in
five cases, a heavy lymphoid component was predominant.
One patient had a concurrent cutaneous marginal zone lym-
phoma (MZL); the additional PCR study showed the presence
of Leishmania DNA in tissue. The results of this study expand
on previous observations as to the deceptive clinicopathologic
manifestations of chronic CL, confirming the diagnostic value
of PCR analysis for Leishmania DNA in unspecified granulo-
matous dermatitides. The authors also suggest that, in coun-
tries where leishmaniasis is endemic, PCR for Leishmania-
spec i f i c DNA be pe r fo rmed in any id iopa th i c
pseudolymphomatous. They also indicate that further study
as to whether chronic Leishmania infection is implicated in
the pathogenesis of some cutaneous MZL is warranted.
Eladl et al. [33] provide further data on the well-known
pitfall of the presence of HRS-like B cells in peripheral T cell
lymphoma (PTCL). They describe 30 such cases from Japan.
Twenty-three cases (77%) were of follicular T-helper pheno-
type (TFH) derivation: 12 were AILT and 11 PTCL with TFH
phenotype (PTCL-TFH). The remaining seven cases were di-
agnosed as PTCL, not otherwise specified (PTCL-NOS).
EBV was detected in 25 cases (83%), but HRS-like B cells
were EBER-positive in only 20 cases (67%). Most of the
patients presented at an advanced clinical stage. The 3-year
overall and progression-free survival rates were 44 and 27%,
respectively. No significant clinicopathological differences
were detected between PTCL-TFH, PTCL-NOS, and the
angioimmunoblastic cases. Although the authors conclude
that HRS-like B cells in a subset of T cell lymphomas were
present more often in elderly patients and associated with
advanced clinical stages and dismal prognosis, the finding is
actually of little practical value.
Prognostic factors in lymphoma
Only a few prognostic studies this time. Koh et al. [34] found
with immunohistochemistry on biopsies from 125 patients
with cHL GLUT1, PD-L1, PD-L2, and PD-1 expression in
45, 63, 10, and 14%, respectively. There was a positive corre-
lation between GLUT1 and PD-L1 expression and between
GLUT1 and PD-L2 expression. GLUT1 expression in HRS
cells was not associated with overall survival or event-free
survival although in the subgroup with high stage, it was
associated with better event-free survival. Hong et al. [35]
measured the pretreatment serum level of survivin in 210
DLBCL patients and analyzed its association with survival
outcome and EBV status, as represented by EBV-encoded
RNA (EBER) in DLBCL. Mean serum survivin level was
higher in patients with relapsed or refractory disease than with
responsive disease. Serum survivin-positive patients had
worse overall and progression-free survival. Serum survivin
positivity was associated with unfavorable characteristics in-
cluding stage. In patients with non-GCB-cell-type DLBCL,
serum survivin-positive patients also had significantly worse
survival than serum survivin-negative patients. EBER-
positivity was found in 7%, and EBER-positive patients had
worse survival. Patients having concomitant positivity for se-
rum survivin and EBER expression showed extremely poor
prognosis. In the present era of rituximab, DLBCLwith serum
survivin positivity showed adverse clinical features and
followed worse clinical course, especially in non-GCB sub-
type DLBCL. EBER-positivity was still associatedwith worse
outcomes in DLBCL. Satou et al. [36] compared the clinico-
pathologic characteristics of 37 cases of MUM1-positive and
51 cases of MUM1-negative BL in Japan. Patients with
MUM1-negative BL were significantly younger and were
more often female. Among the BL patients treated with the
intensive chemotherapy, a standard therapy for BL, MUM1-
positive cases showed worse prognosis. Although the authors
suggest that these two groups need separation, the data are not
strong enough yet for such a conclusion.
Ancillary techniques
Klapper et al. [37] described earlier in this Journal the impor-
tance of a good protocol for the assessment of proliferation by
Ki 67 inMCL. Now, Scott et al. [38] describe a newmolecular
assay for the proliferation signature usable in formalin-fixed
paraffin-embedded material (FFPE), the MCL35 assay, which
contains a 17-gene signature. Forty-seven FFPE biopsies were
used to train the assay on the NanoString platform, using
microarray gene expression data of matched fresh frozen bi-
opsies as a gold standard. Then, the assay was applied to
pretreatment FFPE lymph node biopsies from an independent
cohort of 110 uniformly treated patients. Seventeen biopsies
were tested across three laboratories to assess assay reproduc-
ibility. The yielded gene expression was of sufficient quality
to assign an assay score and risk group in 108 (98%) of the
110. The MCL35 assay assigned patients to high-risk (26%),
standard-risk (29%), and low-risk (45%) groups, with differ-
ent lengths of overall survival: a median of 1.1, 2.6, and
8.6 years, respectively. Concordance of risk assignment across
the three independent laboratories was 100%. The MCL35
assay for FFPE biopsies therefore seems a reliable biomarker,
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but correlation with the extensively used Ki67 index is not yet
done.
Rossi et al. [39] barkon the increasinglypopular liquidbiopsy,
which is actually a hype word for blood test. Nevertheless, the
possibility of deriving genetic data from tumors using a blood
sample has great potential. Using ultra-deep targeted next-
generation sequencing of pretreatment plasma cell-free
(cf)DNA from DLBCL patients correctly discovered DLBCL-
associatedmutations thatwere represented in >20%of the alleles
of the tumorbiopsywith>90%sensitivityand∼100%specificity.
Plasma cfDNA genotyping also allowed for the recovery of mu-
tations that were undetectable in the tissue biopsy, conceivably
because,duetospatial tumorheterogeneity, theywererestrictedto
clones that were anatomically distant from the biopsy site.
Longitudinal analysis of plasma samples collected under
rituximab-cyclophosphamide-doxorubicin-vincristine-
prednisone(R-CHOP)chemotherapyshowedarapidclearanceof
DLBCL mutations from cfDNA among responding patients.
Conversely, amongpatientswhowere resistant toR-CHOP,basal
DLBCL mutations did not disappear from cfDNA. In addition,
among treatment-resistant patients, newmutationswere acquired
in cfDNA that marked resistant clones selected during the clonal
evolution. These results demonstrate that cfDNA genotyping of
DLBCL is as accurate as genotyping of the diagnostic biopsy to
detect clonally represented somatic tumormutations and is a real-
time and noninvasive approach to tracking clonal evolution and
the emergence of treatment-resistant clones. When confirmed,
this approachmay radically alter hematopathology practice.
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